Abstract-Plasma fibrinogen is a major risk factor for coronary heart disease, stroke, and peripheral artery disease. There is evidence that genetic variation in the ␤-fibrinogen gene contributes to the rate of synthesis of fibrinogen, but the molecular mechanism underlying the genetic heritability of the plasma fibrinogen concentration is largely unknown. We evaluated the physiological roles of 5 common nucleotide substitutions in the promoter region of the ␤-fibrinogen gene at positions Ϫ148, Ϫ249, Ϫ455, Ϫ854, and Ϫ993 from the transcriptional start site. Electrophoretic mobility shift assays revealed distinct differences in the binding characteristics of nuclear proteins between wild-type and mutant fragments of both the Ϫ455G/A and Ϫ854G/A polymorphisms, whereas no clear differences were observed for the Ϫ148C/T, Ϫ249C/T, and Ϫ993C/T sites. Transfection studies in HepG2 cells showed increased basal rates of transcription for both the G-to-A substitution at position Ϫ455 (ϩ50%, PϽ0.05) and the G-to-A substitution at Ϫ854 (ϩ51%, PϽ0.05). Additional transfection studies using proximal promoter constructs confirmed that both the Ϫ455A and Ϫ854A alleles independently enhance the basal rate of transcription of the ␤-fibrinogen gene. The rare alleles of the nonrelated Ϫ455G/A and Ϫ854G/A polymorphisms were also associated with significantly increased plasma fibrinogen levels in healthy middle-aged men. Overall, the 2 polymorphisms together explained Ϸ11% of the variation in plasma fibrinogen concentration. It is concluded that the Ϫ455G/A and Ϫ854G/A polymorphisms of the ␤-fibrinogen gene are physiologically relevant mutations with a significant impact on the plasma fibrinogen concentration.
T he notion that fibrinogen is related to cardiovascular disease was originally voiced in the late 1950s, when increased plasma fibrinogen levels were found in patients with coronary heart disease. 1, 2 Since then, substantial epidemiological evidence has accumulated suggesting that the plasma fibrinogen concentration is a major risk factor for coronary heart disease [3] [4] [5] [6] [7] (for review, see Ernst and Resch 8 ), stroke, 3, 9 and peripheral artery disease. 10 However, it remains to be established whether plasma fibrinogen elevation is a cause or consequence of atherosclerotic disease. 8 An elevated plasma fibrinogen concentration in an otherwise healthy individual could be due to the presence of predisposing environmental and/or genetic factors. There is general agreement that smoking is an important environmental factor associated with increased plasma fibrinogen levels. 3, 5, 11, 12 In addition, there is evidence that gender, age, body mass index, and plasma lipoprotein levels may affect the plasma fibrinogen concentration. 13 However, there are conflicting reports regarding the role of specific genetic components in determining plasma fibrinogen levels. Some investigators 14 -16 have reported a substantial contribution of genetic effects on plasma fibrinogen levels, whereas others 17, 18 have reported only minimal genetic influences on plasma fibrinogen levels.
Human fibrinogen is composed of 3 pairs of nonidentical polypeptide chains, denoted ␣, ␤, and ␥, assembled in a bilaterally symmetrical arrangement connected by disulfide bonds. The 3 chains of fibrinogen are encoded by 3 independent genes grouped in a cluster of Ϸ50 kb on chromosome 4 at 4q23 to 32. 19 It has been demonstrated that synthesis of the ␤-fibrinogen protein in hepatocytes is the rate-limiting step in the overall synthesis of the mature fibrinogen protein. 20 Several recent studies have therefore evaluated potential associations between polymorphisms in the ␤-fibrinogen gene and plasma fibrinogen levels. At least 10 common polymorphisms have been described. 10, [21] [22] [23] Several of these are associated with increased plasma fibrinogen concentrations, suggesting that genetic variation in the ␤-fibrinogen gene can contribute to the regulation of plasma fibrinogen levels. However, it was also observed that some of these polymorphisms are in linkage disequilibrium, 23, 24 which makes it difficult to determine the physiological significance of the different mutations.
In the study described here, we screened the proximal promoter of the human ␤-fibrinogen gene in search of common genetic variants with distinct effects on the transcriptional activity of the gene. We demonstrate that 2 nonrelated polymorphisms in the promoter of the ␤-fibrinogen gene (the G-to-A substitution at position Ϫ455 and the G-to-A substitution at Ϫ854) have a substantial impact on the basal rate of transcription of the gene encoding the ␤-fibrinogen chain in vitro. The rare alleles of both polymorphisms are associated with a significantly increased plasma fibrinogen concentration in middle-aged men. Overall, the 2 polymorphisms explained Ϸ11% of the variation in plasma fibrinogen level. It is concluded that the Ϫ455G/A and Ϫ854G/A polymorphisms are physiologically relevant mutations with a significant impact on the plasma fibrinogen concentration.
Methods

Subjects
A total of 210 men aged 35 to 50 years (meanϮSD, 44.9Ϯ5.3 years) were studied. They were recruited randomly from a register of all permanent residents of Stockholm County, Sweden. Of those initially invited, 81% agreed to participate in the research program. All subjects were interviewed to exclude individuals with a history of cardiovascular disease. Additional exclusion criteria were the presence of severely impaired renal function, arteritis, collagenosis, or diabetes mellitus; a history of alcohol abuse or other forms of addiction; and non-Swedish origin.
Blood Sampling, Biochemical Methods, and DNA Procedures
Blood sampling, preparation of plasma, and quantification of major fasting plasma lipoproteins were performed as described by Moor et al. 25 Plasma fibrinogen was measured as described by Clauss 26 using IL test fibrinogen C reagents supplied by Instrumentation Laboratory Spa. The intra-and interassay coefficients of variation for a control plasma sample with a fibrinogen concentration of 2.64Ϯ0.06 g/L (meanϮSD) were 1.8% and 2.2%, respectively. For DNA procedures, nucleated cells from frozen whole blood were prepared as described by to the method of Sambrook et al, 27 and DNA was extracted by a salting-out method. 28 
Gene Sequencing
For nucleotide sequencing of the promoter of the ␤-fibrinogen gene, a 1109-bp section of the proximal promoter, spanning positions Ϫ1074 to ϩ35 (numbers refer to transcriptional start site), was amplified by polymerase chain reaction (PCR) using the forward primer 5Ј-TCCAAACCCTGATAACCTGC and reverse primer 5Ј-GAAGCTCCAAGAAACCATCC. This PCR fragment was used as a template for additional amplifications as part of the Taq DyeDeoxy Terminator Cycle sequencing system (Perkin Elmer). Nested primers, designed on the basis of the published sequence of the promoter of the ␤-fibrinogen gene, 19 were used for analysis of overlapping sections of 200 to 300 bp in both directions.
Genotyping
Genotyping for the Ϫ148C/T, Ϫ249C/T, and Ϫ455G/A polymorphisms was performed using PCR amplification with the forward primer 5Ј-GAACATTTTACCTTATGTGAATTAAGG and reverse primer 5Ј-GAAGCTCCAAGAAACCATCC, followed by digestion with restriction enzymes HindIII, Bsp1286I, and HaeIII, respectively, and subsequent analysis on 2% agarose gels. The genotyping procedure for the Ϫ854G/A mutation used the forward primer 5Ј-GGTGTTCCTATTGATTCTTGTAGG and reverse primer 5Ј-AATGAGGCCCATTTTCCTTGAATT. The reverse primer contained 2 sequence mismatches (underlined), which made it possible to evaluate the Ϫ854G/A mutation using the restriction enzyme EcoRI. After digestion, PCR products were analyzed using 2% MetaPhor agarose (FMC BioProducts).
DNA Constructs
Two sets of double-stranded oligonucleotides were designed for the minimal promoter constructs, constituting the 30-bp sequence around the polymorphic region of either the Ϫ455G/A or Ϫ854G/A mutation, flanked by BamHI and BglII ends. The double-stranded oligonucleotides were ligated head to tail into a BamHI-digested HCAT vector. 29 pCAT plasmids were constructed using 1104-bp promoter fragments, spanning Ϫ1069 to ϩ35, ligated into a pCAT basic vector as described by the supplier (Promega Corporation). Promoter fragments were obtained by PCR amplification of DNA samples from subjects homozygous for the various polymorphisms using the forward primer 5Ј-AACTGCAGACCCTGATAACCT-GCCATC and reverse primer 5Ј-GCTCTAGAGAAGCTCCAA-GAAACCATCC. The correct sequence and orientation of the inserts were tested by DNA sequencing.
Electrophoretic Mobility Shift Assay
Nuclear extracts were prepared according to the method of Alksnis et al. 30 All buffers were freshly supplemented with leupeptin (0.7 g/mL), aprotinin (16.6 g/mL), PMSF (0.2 mmol/L), and 2-mercaptoethanol (0.33 L/mL). The protein concentration in extracts was estimated by the method of Kalb and Bernlohr. 31 Oligonucleotides were designed to represent the 30-bp sequences around the polymorphic region. Pairs of oligonucleotides were annealed at equimolar ratios. The double-stranded oligonucleotides were end-labeled using the T4 polynucleotide kinase method. 27 Incubation for the electrophoretic mobility shift assay (EMSA) was conducted as described by Dawson et al, 32 and the reaction products were applied to 7% (wt/vol) polyacrylamide gel (80:1 acrylamide/ N,NЈ-methylene-bisacrylamide weight ratio), after which electrophoresis was performed in a solution of 22.5 mmol/L Tris, 22.5 mmol/L boric acid, and 0.5 mmol/L EDTA buffer for 2.5 hours at 200 V. Nonradioactive competitor DNAs, either identical, of the opposite allelic variant, or of nonspecific origin, were added in 100-fold excess of the labeled DNA.
The Ϫ455G/A and Ϫ854G/A polymorphisms were analyzed using 2 sets of oligonucleotides and 4 annealing reactions in more than 10 EMSAs.
Transient Transfection Assay
Human hepatoblastoma (HepG2) cells were cultured in 90-mm dishes in DMEM supplemented with 10% FCS. Confluent cells were transfected using the calcium-phosphate DNA coprecipitation method essentially as described by Sambrook et al. 27 The pSV-␤-galactosidase gene (Promega) was cotransfected as an internal control. In all experiments, 5 g of CAT construct and 5 g of ␤-galactosidase plasmid were added to the medium. CAT activity was analyzed as described by the method of Sambrook et al 27 and quantified using a PhosphorImager (bioimaging analyzer BAS-2500, Fuji Photo Film Co). ␤-Galactosidase activity was determined according to the supplier's instructions (Promega). CAT levels were expressed in arbitrary units after standardization for ␤-galactosidase activity. All constructs were tested in triplicate in 4 independent transfection experiments using 2 plasmid preparations.
Statistical Methods
Distribution of continuous variables in groups was expressed as meanϮSD or meanϮSEM. Logarithmic transformation was performed on all skewed variables to obtain a normal distribution before statistical computations and significance testing were performed. Allele frequencies were estimated by gene counting. A 2 test was used to compare the observed numbers of each ␤-fibrinogen genotype with those expected for a population in Hardy-Weinberg equilibrium. The normalized linkage disequilibrium coefficient (DЈ) for the Ϫ455G/A and Ϫ854G/A polymorphisms was calculated according to the method of Ott. 33 One-way ANCOVAs (with age or age and smoking as covariates) and 2-way ANOVAs performed by the general linear model procedure were performed to test whether genetic variation within the ␤-fibrinogen promoter was associated with differences in plasma fibrinogen concentration. The Scheffe multiple comparisons test was used as a post hoc test. The percentage of genotype-based variation in plasma fibrinogen concentration was calculated according to the method of Sing and Davignon. 34 Differences in transcriptional activity between promoter constructs were evaluated by Student's paired 2-tailed t test.
Results
Detection of Common Nucleotide Substitutions in the ␤-Fibrinogen Promoter
A 1109-bp section of the proximal promoter of the ␤-fibrinogen gene was sequenced in both directions using DNA samples from 24 subjects with a broad range of plasma fibrinogen concentrations. Five common nucleotide substitutions were observed in several subjects when comparisons were made with the published nucleotide sequence 19 : a C-to-T substitution at position Ϫ148, a C-to-T substitution at position Ϫ249, a G-to-A substitution at position Ϫ455, a G-to-A substitution at position Ϫ854, and a C-to-T substitution at position Ϫ993.
Allele-Specific Binding of 1 or More Nuclear Proteins to the ؊455G/A and ؊854G/A Polymorphic Sites
We explored the possibility that the nucleotide substitutions in the promoter of the ␤-fibrinogen gene might affect the interaction with nuclear proteins by using an EMSA. The binding characteristics of 30-bp DNA fragments containing either the wild-type or the mutant site for the 5 polymorphisms were evaluated using nuclear extracts derived from HepG2 cells. No differences were observed between the binding characteristics of the wild-type and the mutant DNA fragments of the Ϫ148C/T, Ϫ249C/T, and Ϫ993C/T polymorphisms (data not shown). In contrast, distinct differences between the binding patterns of the wild-type and mutant DNA fragments were observed for the Ϫ455G/A and Ϫ854G/A polymorphisms.
As indicated by the arrows in Figure 1 , 1 major and 1 minor protein-DNA complex were found to be associated with the Ϫ455G allele. The major protein-DNA complex Three protein-DNA complexes were found to be associated with the Ϫ854G-allele ( Figure 3A and 3B, complexes 1 to 3). However, only 1 of the protein-DNA complexes was observed in relation to the Ϫ854A allele ( Figure 3A and 3B, complex 2). A 100-fold excess of unlabeled Ϫ854G fragment effectively reduced the interaction of the labeled Ϫ854G fragment with the nuclear proteins ( Figure 4, lane 3) . In contrast, a 100-fold excess of unlabeled Ϫ854A resulted in a reduction in protein-DNA complex 2 only, whereas no changes were observed in protein-DNA complexes 1 and 3 ( Figure 4, lane 4) .
Similar results were observed with 2 sets of DNA fragments, generated from oligonucleotides purchased from different commercial suppliers and annealed in 4 reactions. Moreover, comparable results were obtained when the binding characteristics of the 3 nuclear extracts were analyzed. Together, the results of the EMSA studies indicate that the nucleotides at positions Ϫ455 and Ϫ854 of the promoter of the ␤-fibrinogen gene are involved in the binding of several different nuclear proteins. The EMSA studies also provided strong evidence of distinct differences between the wild-type Transfection studies in HepG2 cells were conducted to explore whether the Ϫ455G/A and Ϫ854G/A polymorphisms influence the rate of transcription of the ␤-fibrinogen gene. CAT activities were compared between promoter constructs harboring a 30-bp fragment of the ␤-fibrinogen promoter containing either the wild-type or mutant sites of the Ϫ455G/A and Ϫ854G/A polymorphisms upstream of a minimal and heterologous promoter coupled to a CAT reporter gene. As shown in Figure 5 , significantly higher CAT activities were observed for the Ϫ455A construct than for the Ϫ455G construct (150Ϯ11%, PϽ0.005). Moreover, as shown in Figure 6 , significantly higher CAT activities were also observed for the Ϫ854A construct than for the Ϫ854G construct (151Ϯ26%, PϽ0.05).
The rates of transcription of 1104-bp fragments of the proximal promoter spanning from Ϫ1069 to ϩ35 of the ␤-fibrinogen gene containing either the Ϫ249T site, the Ϫ854A site, or the haplotype combination of the Ϫ148T/Ϫ455A/Ϫ993T sites were compared with a fragment containing the wild-type promoter. As shown in Figure 7 , comparable CAT activities were observed for the wild-type promoter and the promoter containing the Ϫ249T site (94Ϯ17%). In contrast, both the plasmid containing the Ϫ854A site (134Ϯ21%, PϽ0.05) and the plasmid containing the Ϫ148T/Ϫ455A/Ϫ993T haplotype (163Ϯ30%, PϽ0.05) had significantly higher CAT activities than the wild-type CAT activities of constructs harboring 30-bp fragments with either the Ϫ455G or Ϫ455A site were compared in transfection studies using HepG2 cells. The constructs were tested in triplicate in 4 independent experiments. CAT activity of the Ϫ455A construct was expressed relative to the activity of the Ϫ455G construct. Bars indicate mean values with SDs. The statistical significance of differences was determined by using Student's paired t test. plasmid. Together, the results from the transfection studies indicate that both the G-to-A substitution at the Ϫ455 position and the G-to-A substitution at position Ϫ854 of the ␤-fibrinogen promoter increase the rate of transcription of the ␤-fibrinogen gene.
Allele Frequencies and Degree of Linkage Disequilibrium
Genotyping for the Ϫ148C/T, Ϫ249C/T, Ϫ455G/A, and Ϫ854G/A polymorphisms was performed in 210 healthy, population-based men aged 35 to 50 years. All polymorphisms were found to be in Hardy-Weinberg equilibrium. The frequencies of the rare Ϫ148T, Ϫ249T, Ϫ455A, and Ϫ854A alleles were 21.4%, 20.2%, 21.4%, and 18.6%, respectively. Complete allelic association was observed between the Ϫ148C/T and Ϫ455G/A polymorphisms. In contrast, the Ϫ249C/T polymorphism was in complete negative linkage disequilibrium with the Ϫ148C/T and Ϫ455G/A polymorphisms. Also, the Ϫ854G/A polymorphism was in complete negative linkage disequilibrium with the Ϫ148C/T and Ϫ455G/A polymorphisms. The normalized linkage disequilibrium coefficient (DЈ) was 0.27 (PϽ0.001) for the 2 functional Ϫ455G/A and Ϫ854G/A polymorphisms. In fact, the 2 polymorphisms were in complete negative linkage disequilibrium in this population; eg, the rare Ϫ854A allele was always present together with the common Ϫ455G allele and vice versa.
Associations Between the ؊455G/A and ؊854G/A Polymorphisms and Plasma Fibrinogen Concentration
The relationships between the Ϫ455G/A and Ϫ854G/A polymorphisms and plasma fibrinogen concentration were determined in the 210 healthy, population-based middle-aged men. As shown in Table 1 , the rare Ϫ455A and Ϫ854A alleles were associated with significantly higher plasma fibrinogen levels than the common Ϫ455G and Ϫ854G alleles. Furthermore, subjects who were homozygous for the Ϫ455A or Ϫ854A allele had higher plasma fibrinogen concentrations than subjects who were heterozygous for these alleles. Smoking had a significant effect on plasma fibrinogen level. Overall, smokers (nϭ75) and nonsmokers (nϭ135) had plasma fibrinogen concentrations of 2.89Ϯ0.45 and 2.72Ϯ0.43 g/L (meanϮSD, PϽ0.001), respectively. No specific interactions between smoking and either the Ϫ455G/A or Ϫ854G/A polymorphism were observed (data not shown).
The influences of the Ϫ455G/A and Ϫ854G/A polymorphisms on the plasma fibrinogen concentration were about equally strong, accounting for 5.4% and 4.4% of the variation in plasma fibrinogen, respectively (Table 1) , when the effects of age and smoking habits were considered in the ANCOVA. To further determine the impact of genetic variation on fibrinogen levels in plasma, genotypes for the 2 polymorphisms were defined and ranked in order of mean fibrinogen values ( Table 2 ). The highest plasma fibrinogen concentrations were encountered in subjects who were homozygous for the Ϫ455G and Ϫ854A alleles. ANCOVA controlling for the influence of age and smoking habits showed that the mean differences in fibrinogen level between Figure 7 . Enhanced transcriptional activities of proximal promoter constructs containing the Ϫ455A and Ϫ854A alleles. CAT activities of 1104-bp promoter constructs containing either the Ϫ249T site, the haplotype combination of the Ϫ148T/Ϫ455A/ Ϫ993T sites (indicated as Ϫ455A), or the Ϫ854A site were compared with a fragment containing the wild-type (WT) promoter. Constructs were tested in triplicate in 4 independent experiments in transfection studies using HepG2 cells. CAT activities of the constructs were expressed relative to the activity of the wild-type construct. Bars indicate mean values with SDs. The statistical significance of differences was determined by Student's paired t test. Values are meanϮSD. One-way ANCOVA (with age and smoking habits as covariates) was performed to test whether genetic variation within the ␤-fibrinogen promoter was associated with differences in plasma fibrinogen concentration. The percentage of genotype-based variation in fibrinogen levels was calculated according to the method of Sing and Davignon. 34 The Scheffe multiple comparisons test was used as a post hoc test to assess differences between genotype groups. *PϽ0.05 compared with homozygotes for the common allele.
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combined genotypes were highly significant ( Table 2 ). The genetic variation associated with the joint Ϫ455G/A and Ϫ854G/A polymorphism accounted for 11.3% of the variation in plasma fibrinogen concentration.
Discussion
The primary aim of this study was to define functional polymorphisms in the human ␤-fibrinogen gene to elucidate the molecular mechanism underlying the genetic heritability of the plasma fibrinogen concentration. Because the synthesis of the ␤ chain is the rate-limiting step in the production of the mature fibrinogen molecule, 20 we concentrated our analysis on the proximal promoter of the ␤-fibrinogen gene. Five common polymorphisms were detected: Ϫ148C/T, Ϫ249C/T, Ϫ455G/A, Ϫ854G/A, and Ϫ993C/T. The Ϫ148C/T, Ϫ249C/T, Ϫ455G/A, and Ϫ854G/A polymorphisms have been described previously, whereas the Ϫ993C/T polymorphism, to the best of our knowledge, has not been reported previously. Strong linkage disequilibrium between the Ϫ148C/T and Ϫ455G/A polymorphisms has been demonstrated by several groups. 23, 24, 35 The Ϫ854G/A polymorphism, on the other hand, which was recently described by Behague et al, 23 was found to be in complete negative linkage disequilibrium with the Ϫ148C/T/Ϫ455G/A polymorphisms; eg, the rare Ϫ854A allele was always present with the common Ϫ455G allele, and vice versa, in the population examined in this study. EMSA studies were conducted as an initial step in the evaluation of the physiological relevance of the 5 promoter polymorphisms. No differences in the binding patterns of the wild-type and mutant probes for the Ϫ148C/T, Ϫ249C/T, and Ϫ993C/T polymorphisms were observed, suggesting that these polymorphisms do not affect the rate of transcription of the ␤-fibrinogen gene. In contrast, significant changes were found in the complex binding patterns of the wild-type and mutant probes for both the Ϫ455G/A and Ϫ854G/A polymorphisms. These allele-specific differences were consistently observed using different probes and different nuclear extracts from HepG2 cells. Moreover, competition studies provided evidence that the changes in binding patterns are related to the specific interaction of several protein-DNA complexes. Together, the results from the EMSA studies suggest that both the Ϫ455G/A and Ϫ854G/A polymorphisms influence the specific binding of several nuclear proteins. Of note, during completion of this study, Brown and Fuller 36 reported, in accordance with the results obtained in this study, the detection of a complex preferentially binding to the Ϫ455G allele.
The physiological roles of Ϫ455G/A and Ϫ854G/A polymorphisms were subsequently analyzed in transfection assays. These studies demonstrated that the basal rates of transcription in HepG2 cells for minimal promoter constructs containing either of the rare Ϫ455A or Ϫ854A sites were higher than the transcriptional activity of constructs containing the wild-type Ϫ455G and Ϫ854G sites, respectively. Essentially similar results were obtained with CAT constructs containing a 1104-bp section of the proximal promoter of the ␤-fibrinogen gene. These results indicate that the rare alleles of the Ϫ455G/A and Ϫ854G/A polymorphisms are both associated with an increase in the basal rate of transcription of the ␤-fibrinogen gene. The nature of the nuclear proteins involved in these protein-DNA complexes and the detailed molecular mechanisms remain to be defined. The present data suggest that the nuclear protein contained in complex 1 that binds preferentially to the Ϫ455A allele is either a stronger transcriptional activator than the nuclear protein contained in complex 2 or that complex 2 acts as a transcriptional repressor. For the Ϫ854 site, on the other hand, it appears that the nuclear proteins contained in complexes 1 and 3 are transcriptional repressors, interfering with the binding of the nuclear protein contained in complex 2, which acts as a transcriptional activator.
There is evidence 13 that the plasma fibrinogen level is influenced by factors like sex, age, chronic disorders (eg, coronary heart disease, hypertension, and diabetes mellitus), and possibly racial background. Potential associations between the Ϫ455G/A and Ϫ854G/A polymorphisms and plasma fibrinogen concentrations were therefore evaluated in a well-defined group of apparently healthy, middle-aged men of Swedish origin. In this population, the Ϫ455G/A and Ϫ854G/A polymorphisms were independently associated with plasma fibrinogen concentration and explained 11.3% of the variation in plasma fibrinogen levels.
A significant relationship between the Ϫ455G/A polymorphism and plasma fibrinogen levels has been documented in several reports. 13, 21, 23, [37] [38] [39] [40] [41] [42] It appears from these studies that the overall impact of the Ϫ455G/A polymorphism on the plasma fibrinogen concentration is rather small. For instance, investigators from the Copenhagen City Heart Study 13 reported that the Ϫ455G/A polymorphism explained only 1% of the variation in plasma fibrinogen level. The relationship between the Ϫ854G/A polymorphism and plasma fibrinogen level, on the other hand, has thus far been evaluated in only 1 study. 23 It was reported that the effect of the Ϫ854G/A polymorphism was insignificant in univariate analysis but became significant after adjustment for the Ϫ455G/A polymorphism. Previous reports thus suggest that the impact of the Ϫ455G/A and Ϫ854G/A polymorphisms on the plasma fibrinogen concentration is limited. However, in our study, we found a significant contribution of both the Ϫ455G/A and Values are meanϮSEM. One-way ANCOVA (with age and smoking habits as covariates) was performed to test whether genetic variation within the ␤-fibrinogen promoter was associated with differences in plasma fibrinogen concentration. The percentage of genotype-based variation in fibrinogen levels was calculated according to the method of Sing and Davignon. 34 The Scheffe multiple comparisons test was used as a post hoc test to assess differences between genotype groups. *PϽ0.05 compared with the Ϫ455GG/Ϫ854GG genotype.
Ϫ854G/A polymorphisms to the plasma fibrinogen concentration. Moreover, the 2 polymorphisms together explained Ϸ11% of the plasma fibrinogen concentration. This indicates that the impact of the Ϫ455G/A and Ϫ854G/A polymorphisms on the plasma fibrinogen concentration may be larger than previously reported. It is likely that discrepancies between studies are in part due to differences in selection criteria of the populations analyzed. However, it is noteworthy that in the only study in which the 2 polymorphisms were compared directly, 23 it was found that the Ϫ455G/A and Ϫ854G/A polymorphisms were incompletely dissociated and not in complete allelic dissociation as was observed in this study. This points to subtle genetic differences between Swedish subjects and other European populations, although inaccuracies in genotyping may also have contributed to this phenomenon.
It seems reasonable to assume that the observations described above regarding the Ϫ455G/A and Ϫ854G/A polymorphisms are interrelated and part of a sequence of events starting at the level of the ␤-fibrinogen gene and ultimately leading to increased plasma fibrinogen concentration. We thus propose that the 2 mutations affect the binding of hepatic nuclear factors to the promoter of the ␤-fibrinogen gene, resulting in an increase in ␤-fibrinogen transcription and enhanced secretion of mature fibrinogen by the liver, ultimately leading to increased plasma fibrinogen levels. However, it must be stressed that we cannot formally exclude the possibility that other mutations, linked to either the Ϫ455G/A or Ϫ854G/A polymorphism, may influence the metabolism of fibrinogen.
